Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 144

1.

Summary of the role of statins in the treatment of dyslipidemia.

Carr LL.

J Am Osteopath Assoc. 2003 Jul;103(7 Suppl 3):S1-3. Review. No abstract available.

PMID:
12884937
2.

Management of metabolic syndrome: statins.

Xydakis AM, Ballantyne CM.

Endocrinol Metab Clin North Am. 2004 Sep;33(3):509-23, vi. Review.

PMID:
15262294
3.
4.

The 2003 Canadian recommendations for dyslipidemia management: revisions are needed.

Manuel DG, Tanuseputro P, Mustard CA, Schultz SE, Anderson GM, Ardal S, Alter DA, Laupacis A.

CMAJ. 2005 Apr 12;172(8):1027-31. No abstract available. Erratum in: CMAJ. 2005 Jul 19;173(2):133.

5.

[Clinical trials on protective efficacy of statins for cardiovascular events due to hyperlipidemia (J-LIT, 4S, CARE, LIPID etc)].

Higashikata T.

Nihon Rinsho. 2004 Mar;62 Suppl 3:628-36. Review. Japanese. No abstract available.

PMID:
15171447
6.

Lipid and nonlipid benefits of statins.

Chilton RJ.

J Am Osteopath Assoc. 2003 Jul;103(7 Suppl 3):S12-7.

PMID:
12884939
7.

Management of dyslipidemias in the age of statins.

Green ML.

Prim Care. 2003 Dec;30(4):641-69. Review.

PMID:
15024890
8.

[What other effects do statins have except their effect on lipids?].

Tikkanen MJ.

Duodecim. 1998;114(13):1299-301. Finnish. No abstract available.

PMID:
11552256
9.

Reaching goal: conquering the treatment gaps in dyslipidemia management.

Brown WV.

Clin Cardiol. 2003 Apr;26(4 Suppl 3):III1-2. No abstract available.

10.

[Treatment of dyslipidemia].

Cybulska B.

Pol Merkur Lekarski. 2002 Nov;13 Suppl 1:11-2. Polish. No abstract available.

PMID:
12621774
11.

Weight of the evidence in statin clinical trials: comparing the results.

Clearfield MB.

J Am Osteopath Assoc. 2003 Jul;103(7 Suppl 3):S4-11. Review.

PMID:
12884938
12.

Clinical aspects of dyslipidemia.

Kashyap M.

Manag Care. 2001 Nov;10(11 Suppl):4-9; discussion 19-24. No abstract available.

13.

C-reactive protein and lipids may respond differently to statins.

Black DM.

Curr Atheroscler Rep. 2003 Jan;5(1):9. No abstract available.

PMID:
12562533
14.

Management of dyslipidemia in patients with complicated metabolic syndrome.

Davidson MH.

Am J Cardiol. 2005 Aug 22;96(4A):22E-25E. Review.

PMID:
16098839
15.

Statins, low cholesterol, and hemorrhagic stroke: an uncertain triangle.

Jacobs BS, Greenberg SM.

Neurology. 2008 Jun 10;70(24 Pt 2):2355-6. doi: 10.1212/01.wnl.0000314696.61422.12. No abstract available.

PMID:
18541869
16.

Trends in statin use and low-density lipoprotein cholesterol levels among US adults: impact of the 2001 National Cholesterol Education Program guidelines.

Mann D, Reynolds K, Smith D, Muntner P.

Ann Pharmacother. 2008 Sep;42(9):1208-15. doi: 10.1345/aph.1L181. Epub 2008 Jul 22.

PMID:
18648016
17.

Is it necessary to add fibrate to statin therapy in the management of dyslipidemia of metabolic syndrome?

Turhan H, Yetkin E.

Int J Cardiol. 2006 Jun 16;110(2):276-7. Epub 2005 Dec 20.

PMID:
16364471
18.

[Statins].

Kobayashi J.

Nihon Rinsho. 2006 Dec 28;64 Suppl 9:618-21. Review. Japanese. No abstract available.

PMID:
17458292
19.

Management of atherogenic dyslipidemia of the metabolic syndrome: evolving rationale for combined drug therapy.

Vega GL.

Endocrinol Metab Clin North Am. 2004 Sep;33(3):525-44, vi. Review.

PMID:
15262295
20.

Effects of lipid-altering treatment in diabetes mellitus and the metabolic syndrome.

Deedwania PC, Hunninghake DB, Bays H.

Am J Cardiol. 2004 Jun 3;93(11A):18C-26C. Review.

PMID:
15178513

Supplemental Content

Support Center